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Acute lymphoblastic leukemia (ALL) in
second complete remission is one of the
most common indications for allogeneic
hematopoietic stem cell transplantation
(HSCT) in pediatric patients. We com-
pared the outcome after HCST of adoles-
cents, aged 14 to 18 years, with that of
children (ie, patients < 14 years of age).
Enrolled in the study were 395 patients
given the allograft between January 1990
and December 2007; both children (334)
and adolescents (61) were transplanted in
the same pediatric institutions. All pa-
tients received a myeloablative regimen
that included total body irradiation in the
majority of them. The donor was an HLA-
identical sibling for 199 patients and an
unrelated volunteer in the remaining
196 patients. Children and adolescents
had a comparable cumulative incidence
of transplantation-related mortality, dis-
ease recurrence, and of both acute and
chronic graft-versus-host disease. The
10-year probability of overall survival and
event-free survival for the whole cohort of
patients were 57% (95% confidence inter-
val, 52%-62%) and 54% (95% confidence
interval, 49%-59%), respectively, with no
difference between children and adoles-
cents. This study documents that adoles-
cents with ALL in second complete remis-
sion given HSCT in pediatric centers have
an outcome that does not differ from that
of patients younger than 14 years of age.
(Blood. 2011;118(25):6683-6690)
Introduction
Nowadays, intensive and risk-adapted chemotherapy protocols
cure more than 80% of children with acute lymphoblastic leukemia
(ALL).1,2 Disease recurrence remains the leading cause of treat-
ment failure in childhood ALL.3 Among ALL patients developing
recurrence, a substantial proportion achieves a second complete
remission (CR), although final outcome remains still unsatisfac-
tory. In this respect, survival of patients experiencing relapse can be
predicted by site of relapse, duration of first complete remission,
and immunophenotype of ALL. Bone marrow (BM) relapse and
early relapse (ie, occurring within 6 months from treatment discon-
tinuation), as well as T-lineage ALL, have worse prognosis than
isolated extramedullary or late relapse (ie, those occurring more
than 6 months from treatment discontinuation).3 Allogeneic hema-
topoietic stem cell transplantation (HSCT) is largely used in the
post-remission treatment of children and adolescents with ALL in
second CR (CR2).3 In the past, analysis of factors influencing the
outcome of patients transplanted from an unrelated volunteer
showed that adolescents had a poorer outcome compared with
children.4,5 With the aim of verifying whether this difference is
confirmed in another cohort, we compared the outcome of HCST in
adolescents, defined as 14 years or older, with that of children
younger than 14 years, with relapsed ALL who were reported to the
Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP).
Patients and methods
Patients
Enrolled in the study were 395 patients (256 males and 139 females)
younger than 18 years, with ALL in CR2 after either isolated or combined
extramedullary/BM relapse, who have received a first allogeneic HSCT
from either a matched family donor (MFD) or an unrelated donor (UD) in
one of the 18 AIEOP centers performing allogeneic HSCT. Patients were
given the allograft between January 1, 1990, and December 31, 2007, and
were reported to the AIEOP-HSCT Registry. Data concerning patient and
disease characteristics, as well as transplantation outcome, were collected
by a standardized questionnaire for each patient enrolled.
Histocompatibility for all donor–recipient pairs was determined by
serology or low-resolution molecular typing for HLA-A and -B antigens
and high-resolution allelic technique for DRB1. All MFD pairs were A, B,
DRB1 matched. Since 1998, high-resolution molecular typing also has been
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performed for HLA class I loci in most of patients transplanted from an UD,
and we defined this characterization as high-resolution typing. Pairs
matched for HLA-A, -B, and -DRB1 were defined as 6/6-loci matched,
whereas pairs in which there was incompatibility for a single HLA locus
were defined as 5/6-loci matched. All UD pairs were either 5- or 6-loci
matched.
At time of transplantation, 334 patients were younger than 14 years,
whereas the remaining 61 patients where 14 years or older, henceforth
defined as adolescents.
In both groups,  90% of the transplants were performed using BM
stem cells. Preparative regimens varied, mainly depending on patient age
and center choice. Nevertheless, all patients received a myeloablative
conditioning regimen that included total body irradiation in 89% of the
cases, most often associated with thiotepa and cyclophosphamide.6
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclospor-
ine (CsA) alone for 87% of MFD recipients and of a combination of
CsA, short-term methotrexate and rabbit anti-thymocyte globulin
(2.5-3.75 mg/kg/day from day 4 to day 2) for 77% of UD recipients.
The children and adolescent groups were comparable for all the variables
analyzed, except for the median white blood cell count at diagnosis that was
higher in the former group (see Table 1 for details).
Acute and chronic GVHD (aGvHD, cGvHD) were diagnosed and
graded according to the Seattle criteria.7,8 Patients surviving more than
14 and 100 days after transplantation were evaluated for aGvHD and
cGvHD occurrence, respectively. Whenever clinically indicated and fea-
sible, tissue biopsy samples were obtained to confirm the diagnosis of
GVHD.9,10
Myeloid engraftment was defined as the first of 3 consecutive days
when neutrophil count was  0.5  109/L, and platelet engraftment was
defined as the first of 7 consecutive days with an unsupported platelet count
 50  109/L.
Children were stratified into 4 risk groups (S1, S2, S3, and S4),
according to the Berlin-Frankfurt-Munster (BFM) classification of ALL
relapses, based on immune-phenotype, site of relapse, and time elapsed
from diagnosis to relapse.11 On this basis, 17% of the children and 21% of
the adolescents were included in the S4 group consisting of patients
experiencing marrow relapse, of either T-lineage ALL, irrespective of the
time interval between diagnosis and recurrence, or of B-lineage ALL, if
relapse occurred within the first 18 months after diagnosis. Eleven percent
of the children and 3% of the adolescents were included in the S3 group
consisting of isolated marrow relapses of B-lineage ALL occurring
18 months after diagnosis and within 6 months after treatment discontinua-
tion. Forty-two percent of the children and 43% of the adolescent were
included in the S2 groups consisting of isolated or combined marrow
relapse of B-lineage ALL occurring more than 6 months after treatment
discontinuation, and combined marrow relapses of B-lineage ALL occur-
ring later than 18 months after diagnosis and within 6 months after
treatment discontinuation. Three percent of children and none of the
adolescents were included in the S1 group, the group associated with the
best prognosis and comprises patients with isolated extramedullary relapses
occurring later than 6 months after treatment discontinuation. One hundred
ten patients could not be included in any of the BFM class of risk because of
lack of the relevant data needed for stratification. Details on patient
stratification are presented in Table 1.
Statistical analysis
Patients’ data were collected using patient-oriented forms, filled in by a
physician in charge at each center, and sent to the AIEOP Operation Office
in Bologna. There the data were stored in an electronic database (AIEOP-
HSCT Registry) and analyzed for quality control and statistical analysis by
Venus, a facilities-integrated software system running on an IBM main-
frame at the Italian Inter-University Computing Center.
The primary aim of this study was to evaluate the impact of patient age
on the outcome of HSCT in ALL in CR2. We also evaluated the impact on
outcome of the following patient-, donor-, and transplantation-related
factors: recipient sex, interval between diagnosis and HSCT, interval
between relapse and HSCT, BFM risk class at relapse, donor age,
donor–recipient sex mismatch, human cytomegalovirus serology for both
donor and recipient, conditioning regimen (total body irradiation vs
chemotherapy), year of transplantation, number of infused BM–nucleated
cells, and occurrence of aGvHD and cGvHD.
Quantitative variables are reported as median and range, whereas
categorical variables are expressed as absolute number and percentage.
Demographic and clinical characteristics of the 2 groups of patients were
compared using the 2 test or Fisher exact test for categorical variables
(eg, sex, disease, conditioning regimen, HLA matching), whereas the
Mann-Whitney rank sum test and the student t test were used for continuous
variables (eg, age, time interval between diagnosis and HSCT, marrow cell
dose), as appropriate.
Overall survival (OS) was defined as the probability of survival,
regardless of disease status, at any time point; surviving patients were
censored at last follow-up, whereas only death was considered an event.
Event-free survival (EFS) was defined as the probability of being alive and
disease-free at any time point; both death and relapse were considered
events, whereas patients who were alive and disease free were censored at
last follow-up. Relapse rate (RR) was defined as the probability of having a
relapse at time t, death in remission being considered the competing event.
On the contrary, treatment-related mortality (TRM) was defined as the
probability of dying without previous occurrence of relapse, which was
considered to be the competing event. Acute and cGVHD were defined as
the probabilities to develop either grade II-IV or grade III-IV aGvHD or
cGvHD, considering both graft failure and TRM as competing events.12 OS,
EFS, RR, TRM, aGvHD, and cGvHD were estimated from the date of
transplantation to the date of the statistical analysis or to the date of an
adverse event. All results are expressed as 10-year probability or 10-year
cumulative incidence (percentage) and 95% confidence interval (95% CI).13
Probabilities of OS and EFS were calculated according to the Kaplan-
Meier method.14 RR, TRM, aGvHD, and cGvHD were calculated as
cumulative incidence curves to adjust the estimates for competing risks.15,16
The significance of differences between EFS curves was estimated by the
log-rank test (Mantel–Cox), whereas the Gray test was used to assess, in
univariate analyses, differences between the cumulative incidences of RR,
TRM, aGvHD, and cGvHD.17
All variables with a P value  0.1 in univariate analysis were included
in a multivariate analysis of EFS, performed using the Cox proportional
hazard regression model.18 The proportional subdistribution hazard regres-
sion model was used to perform multivariate analyses of RR and TRM.19
Statistical analysis was performed using the R 2.5.0 software package
(http://www.R-project.org).20,21 Data were analyzed as of May 15, 2010.
Results
The median observation time for surviving patients, considering
the whole study population, was 8 years (range, 2-20 years); it was
8.7 years for children and 7.0 years for adolescents (P  N.S.).
Engraftment and GVHD
Three patients (1%) died before engraftment; the remaining
392 patients engrafted. No significant differences in myeloid and
platelet recovery were observed between the 2 groups (data not
shown).
The 100-day cumulative incidence (Figure 1) of grade II-IV
aGvHD in children or adolescents was 54% (95% CI, 49%-60%)
and 49% (95% CI, 37%-66%; P  N.S.), whereas the 100-day
cumulative incidence of grade III-IV aGvHD was 19% (95% CI,
15%-24%) and 14% (95% CI, 7%-28%), respectively (P  N.S.).
One hundred and one (34%) of the 300 patients at risk (ie,
surviving at least 100 days after HSCT) developed cGvHD that
was limited in 63 cases (21%) and extensive in the remaining
38 (13%). The cumulative incidence of cGvHD was 32% (95% CI,
27%-38%) for children and 43% (95% CI, 31%-60%) for adoles-
cents (P  N.S.), respectively. In 4 cases, cGvHD had de novo
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Table 1. Clinical characteristics of the 395 patients enrolled in the study and comparison between children and adolescents
Characteristic
Children Adolescents
Pn (%) n (%)
No. of patients 334 (100) 61 (100)
Sex
Male 212 (63) 44 (72) N.S.
Female 122 (37) 17 (28)
Median age at diagnosis, y (range) 4.9 (1.1-13) 13.3 (5.6-16.9)  .001
Median WBC at diagnosis, 109/L (range) 14.5 (0.1-430) 8.1 (0.3-311) 0.01
Immunophenotype
B-lineage ALL 215 (64) 35 (57) .08
T-lineage ALL 26 (8) 10 (16)
Missing/unknown 93 (28) 16 (26)
Cytogenetic abnormalities
t(9;22) 12 (4) 3 (5) N.S.
Frontline chemotherapy protocol
AIEOP LAL 82 6 (2) 0 (0) N.S.
AIEOP LAL 87 24 (7) 5 (8)
AIEOP LAL 88 20 (6) 2 (3)
AIEOP LAL 91 71 (21) 11 (18)
AIEOP LAL 95 116 (34) 17 (28)
AIEOP LAL 2000 87 (27) 21 (35)
Other 10 (3) 5 (8)
Median interval between diagnosis and first relapse, mo (range) 29 (2-121) 33 (3-102) N.S.
Relapse timing
Very early relapse 18 mo from diagnosis 69 (21) 13 (21) N.S.
Early relapse 18-30 mo from diagnosis 94 (28) 13 (21)
Late relapse 30 mo from diagnosis 159 (48) 32 (53)
Missing/unknown 12 (3) 3 (5)
Site of first relapse
BM 232 (69) 40 (65) N.S.
Combined BM  extramedullary 40 (12) 9 (15)
Isolated extramedullary 40 (12) 6 (10)
Missing/unknown 22 (7) 6 (10)
BFM class at relapse
S1 9 (3) 0 (0) N.S.
S2 141 (42) 26 (43)
S3 38 (11) 2 (3)
S4 56 (17) 13 (21)
Missing/unknown 90 (27) 20 (33)
Median age at HSCT, y (range) 8.3 (1.5-14) 16 (14-18)  .001
Median interval between diagnosis and HSCT, y (range) 2.9 (0.5-10) 3.3 (0.5-8.8) N.S.
Donor
MFD 168 (50) 31 (51) N.S.
UD 166 (50) 30 (49)
HLA typing resolution for UD
High resolution 113 (68) 21 (70) N.S.
Low resolution 53 (32) 9 (30)
Stem cell source
BM 314 (94) 55 (90) N.S.
PB 20 (6) 6 (10)
Infused cell dose
BM, nucleated cells  108/kg (range) 4.2 (1-11.1) 3.1 (1.3-5.9) N.S.
PB, CD34 cells  106/kg (range) 10.6 (3.3-18.7) 6.1 (5.0-10.1) N.S.
Conditioning regimen
TBI 301 (90) 56 (92) N.S.
Chemotherapy 31 (9) 5 (8)
Missing/unknown 2 (1) 0 (0)
GvHD prophylaxis
MFD
CsA  PDN 151 (90) 24 (77) N.S.
CsA  ATG 4 (2) 0 (0)
CsA  MTX 12 (7) 5 (16)
CsA  MTX  ATG 1 (1) 2 (7)
UD
CsA  PDN 3 (1) 0 (0) N.S.
CsA  ATG 7 (4) 1 (3)
CsA  MTX 29 (18) 3 (10)
CsA  MTX  ATG  PDN 127 (77) 26 (87)
WBC indicates white blood cell; PB, peripheral blood; TBI, total body irradiation; PDN, prednisone; ATG, anti-thymocyte globulin; MTX, methotrexate; and N.S., not
significant.
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onset, whereas aGvHD preceded cGvHD in the remaining
97 patients.
Transplant-related mortality
Eighty-five patients (22%) died of transplantation-related causes at
a median time of 89 days (range, 5 days-6 years) after the allograft.
Details on causes and timing of death are reported in Table 2.
The 100-day and 10-year cumulative incidences of TRM were
12% (95% CI, 9%-16%), and 22% (95% CI, 18%-27%) for
children and 18% (95% CI, 11%-31%) and 23% (95% CI,
14%-36%) for adolescents, respectively, with no statistically
significant difference between the 2 groups (Figure 1).
Transplants from an UD (P  .0001), especially if typed with
low-resolution techniques (P  .0001), occurrence of grade IV
aGvHD (P  .0001) and of extensive cGvHD (P  .0001), were
significantly associated, in univariate analysis, with a higher risk of
TRM (Table 3). Among patients transplanted from an UD, the
cumulative incidence of TRM was significantly higher before 2000
and when low-resolution HLA typing was performed (see Table 3
for details). Multivariate analysis confirmed that recipients of
transplantation from an UD typed with low-resolution techniques,
patients who experienced grade IV aGvHD, and those who
developed cGvHD had a significantly increased risk of TRM
(Table 4).
Relapse
Leukemia relapse occurred in 93 patients (24%) at a median time of
186 days after the allograft (range, 29 days-5.5 years). The cumula-
tive incidence of relapse for children and adolescents was 25%
(95% CI, 20%-39) and 22% (95% CI, 14-36), respectively
(P  N.S.; Figure 1), with no difference in the timing of relapse
between the 2 groups. Details on the timing of disease-related
deaths are reported in Table 2.
Univariate analyses demonstrated that S3 and S4 BFM classes
of risk (P  .0001), absence of both aGvHD (P  .0001) and use
of a chemotherapy-based conditioning regimen were associated
with an increased risk of disease recurrence after HSCT (Table 3).
Multivariate analysis confirmed that the former 2 of these 3 risk
factors remained significantly correlated with an increased risk of
relapse (Table 4).
Overall and event-free survival
Overall, 164 patients died at a median of 6 months after transplan-
tation, with the values for children and adolescents being 6 months
(range, 11 days-6 years) and 5 months (range, 5 days-1.8 years),
respectively (P  N.S.; Figure 2). On the whole, 231 patients
(58%) were alive at time of data analysis and 217 of them (55% of
the study population) were disease-free. The 10-year Kaplan–
Meier estimates of OS and EFS were 57% (95% CI, 52%-62%) and
54% (95% CI, 49%-59%), respectively, for the whole cohort of
patients. The 10-year EFS was 54% (95% CI, 49%-60%) for
children and 54% (95% CI, 41%-67%) for adolescents, respec-
tively (P  N.S.; Figure 2).
Univariate analysis of the different patient-, donor-, and trans-
plantation-related characteristics potentially influencing the clini-
cal outcome showed that male sex (P  .01), S3 and S4 BFM risk
class at first relapse (P  .0001), UD donor (P  .02), and either
absence or grade IV aGvHD (P  .0001) significantly correlated
with a lower EFS (Table 3). Because of the lower risk of TRM,
patients transplanted from an UD donor after 2000 had a better
probability of EFS, comparable with that of patients transplanted
from an MFD in the same time period (see Table 3 for details).
Likewise, patients transplanted from an UD selected using high-
resolution molecular typing had a probability of EFS similar to that
of patients given the allograft from an MFD and significantly better
than that of patients transplanted from an unrelated volunteer
selected using low-resolution typing. S3 and S4 BFM class at first
relapse and absence of aGvHD remained significantly associated
with a worse EFS also in the multivariate Cox regression model
(Table 4).
Discussion
Age has been reported to have a significant impact on survival in
pediatric patients with ALL, as well as on the clinical outcome of
patients receiving allogeneic HSCT.2,4,5,22
Adolescent patients with cancer are a peculiar population,
because they are at a unique point in their lives where autonomy
must be balanced with guidance and support from their families
and treating physicians. According to data provided by the Italian
Association of Tumor Registries, each year 80 adolescents are
expected to be diagnosed with ALL in Italy.23 An analysis carried
out by the Epidemiology and Biostatistics Working Group of the
AIEOP on patients diagnosed between 2001 and 2006 showed that
only 43% of the Italian adolescents with ALL were diagnosed and
treated in AIEOP institutions, with the remaining part being treated
in adult centers (Roberto Rondelli, Clinica Pediatrica Universita` di
Figure 1. Cumulative incidence of TRM and relapse for ALL CR2 patients. Curves representing TRM (top) and relapse (bottom) are shown for children ( 14 years of age;
dotted line) and adolescents ( 14 years of age; continuous line). P  N.S. N indicates number; E, events.
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Bologna, Policlinico Sant’Orsola–Bologna, personal communica-
tion, January, 2011). Thus, the adolescents may be treated by either
pediatric or adult oncologists. As such, the treating physicians,
including transplanters, may view the 14- to 18-year-old patient as
an older child or as a younger adult.
Two questions need to be answered before defining how and where
adolescents should be treated. Which is the best frontline therapy for
this group of patients? Who should be responsible for HSCT?
In general, adolescents compared with children with cancer tend
to have worse OS and health outcomes at the end of treatment, with
this difference possibly being because of the treatment protocol
used. In this particular regard, many retrospective analyses of the
adolescent age group with newly diagnosed ALL treated according
to either pediatric or adult protocols showed a statistically signifi-
cantly superior outcome for patients treated with pediatric regi-
mens.22,24,25 A lower relapse rate accounted for the superior results
observed in adolescents treated according to pediatric protocols.
Several factors may have contributed to explain this different
outcome, which cannot be interpreted in view of differences in the
distribution of prognostic factors between the population enrolled
in pediatric and in adult trials. A major role is certainly played by
differences in protocol design and treatment intensity, with pediat-
ric protocols including more non-myelosuppressive drugs with
demonstrated activity on ALL blasts, such as L-asparaginase,
glucocorticoids, and vincristine.22,24,25 Moreover, central nervous
system prophylaxis was administered earlier, with greater fre-
quency and for a more prolonged period in pediatric trials.22,24,25 A
minor role also may be played by a more accurate administration of
therapy in pediatric institutions, because of a peculiar attitude of
pediatricians concerning the need to maintain the prescribed doses
and schedules, and a possibly better compliance of adolescent
patients treated in a pediatric facility.26 Actually, worldwide, the
outcome of adolescents with ALL has significantly improved over
time.2,22,24-28 Patients enrolled in our study were treated according
Table 2. Causes and timing of death in study population
Children
(n 334)
Adolescents
(n 61)
First
100 d
after
HSCT
After
100 d
from
HSCT
First
100 d
after
HSCT
After
100 d
from
HSCT
Total
(N 395)
Cause of death
aGvHD 12 6 2 0 20
cGvHD 0 9 0 2 11
Hemorrhage 3 1 2 0 6
ARDS 3 1 0 0 4
Idiopathic pneumonia 1 1 1 0 3
Aspergillus pneumonia 2 1 0 0 3
Pneumocystis pneumonia 0 0 1 0 1
HCMV pneumonia 2 0 0 1 3
Bacterial infections 6 6 2 0 14
Fungal infections 2 0 0 0 2
Viral infections 1 1 1 0 3
Veno-occlusive disease 1 1 1 0 3
Multiorgan failure 4 4 1 0 9
EBV-PTLD 2 0 0 0 2
TTP 1 0 0 0 1
Total transplant-related deaths 40 31 11 3 85
Disease progression 4 64 1 10 79
Total 44 95 12 13 164
ARDS indicates acute respiratory distress syndrome; HCMV, human cytomega-
lovirus; EBV-PTLD, Epstein-Barr virus–related post-transplant lymphoproliferative
disease; and TTP, thrombotic thrombocytopenic purpura.
Table 3. Ten-year EFS, RR, and TRM according to recipient, donor,
and transplant characteristics: univariate analyses
Variable
EFS, %
(95% CI)
RR, %
(95% CI)
TRM, %
(95% CI)
Age at transplant
Children 54 (49-60) 24 (20-29) 22 (18-27)
Adolescents 54 (41-67) 23 (15-36) 23 (14-36)
P N.S. N.S. N.S.
Sex
Male 49 (42-55) 26 (22-33) 25 (20-31)
Female 65 (57-73) 19 (13-27) 16 (11-24)
P 0.0051 N.S. 0.059
Immunophenotype
B lineage 55 (49-61) 23 (18-28) 22 (18-28)
T lineage 47 (31-63) 28 (16-47) 25 (14-44)
P N.S. N.S. N.S.
BFM class at relapse
S1  S2 63 (55-70) 17 (12-24) 20 (15-27)
S3  S4 38 (28-47) 37 (29-47) 26 (19-35)
Unknown 58 (48-68) 21 (15-30) 21 (14-31)
P  0.0001 0.0002 N.S.
Year of HSCT, all pts
Before 2000 49 (41-56) 28 (22-36) 23 (18-31)
2000 or later 58 (51-65) 21 (16-27) 21 (16-27)
P 0.046 0.083 N.S.
Year of HSCT, MFD
Before 2000 55 (46-64) 30 (23-39) 15 (10-23)
2000 or later 65 (53-76) 20 (13-31) 15 (8-27)
P N.S. N.S. N.S.
Year of HSCT, UD
Before 2000 35 (22-48) 24 (15-39) 41 (30-56)
2000 or later 55 (46-63) 21 (15-30) 24 (18-32)
P 0.0072 N.S.  0.0001
Donor
MFD 59 (52-66) 26 (20-33) 15 (11-21)
UD 50 (42-57) 22 (17-29) 29 (23-36)
P 0.022 N.S. 0.0006
HLA typing resolution
MFD 59 (52-66) 26 (20-33) 15 (11-21)
HR UD 57 (48-65) 21 (15-29) 22 (16-31)
LR UD 35 (23-47) 23 (14-36) 42 (31-56)
P 0.0003 N.S.  0.0001
Conditioning regimen
TBI  CHT 56 (51-61) 23 (19-27) 22 (18-26)
CHT alone 44 (27-60) 31 (19-50) 26 (15-45)
P N.S. 0.011 N.S.
Infused nucleated cells
 4  108/kg 57 (49-64) 22 (17-29) 21 (16-28)
 4  108/Kg 57 (49-64) 26 (20-33) 18 (13-25)
P N.S. N.S. 0.0009
aGvHD grade
0 15 (1-28) 67 (51-87) 19 (8-41)
I 66 (57-75) 23 (16-32) 11 (7-19)
II 64 (56-73) 20 (14-29) 15 (10-23)
III 58 (40-75) 16 (7-36) 27 (15-47)
IV 14 (1-27) 4 (1-24) 82 (69-98)
P  0.0001  0.0001  0.0001
cGvHD
Absent 66 (59-72) 28 (23-35) 6 (4-11)
Limited 76 (66-87) 12 (6-23) 11 (6-23)
Extensive 57 (41-73) 22 (12-40) 21 (11-39)
P N.S. 0.054  0.0001
The log-rank test was used for comparisons of EFS probabilities, whereas the
Gray test was used to compare cumulative incidences of relapse and TRM.
HR indicates high-resolution HLA typing (4 digits) for both first- and second-class
HLA antigens; LR, low-resolution HLA typing (2 digits) for first-class HLA antigens and
high-resolution HLA typing (4 digits) for second-class HLA antigens; CHT, chemo-
therapy; and N.S., not significant.
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to frontline protocols of several studies, namely, AIEOP ALL 82,
87, 88, 91, 95, and 2000, which showed a continuous improvement
in final outcome. Indeed, the 15-year EFS increased from 52.5%
for the 902 eligible patients included in the study 82 to 67.7% for
the 1192 children enrolled in study 91.2 The 10-year EFS of in the
1743 eligible patients enrolled in study 95 was 71.7%,2 whereas,
for what concerns patients treated according to the study AIEOP-
BFM 2000, those with B-cell precursor (4016 children) and
T-lineage ALL (464 children) had a 7-year EFS of 80.4% and
75.9%, respectively.28,29 The improved outcome of patients treated
with frontline chemotherapy in Italy was documented in both
children and adolescents (data not shown).
Concerning transplantation, previously published studies re-
ported that in pediatric patients older age also has a relevant impact
on the probability of EFS after HSCT.4,5,30 Indeed, Bunin et al
reported that patients more than 15 years of age undergoing UD
HSCT for ALL had a worse outcome than younger patients, with
TRM being 60% in the former compared with 38% in the latter
patients.4 For a correct and meaningful interpretation of these
results, it has to be highlighted that the 363 patients analyzed in that
study were treated in several institutions without homogeneous risk
criteria at diagnosis, with different both frontline and post-relapse
therapy protocols, and varying conditioning regimens.
A study by Woolfrey et al on UD HSCT for childhood ALL
showed that both advanced disease phase (P  .0001) and age
more than 10 years (P  .002) were predictors of worse outcome.5
In multivariate analyses, older age correlated with greater risk of
aGvHD and organ toxicity, with these conditions lead to an
increased TRM. More recently, a retrospective survey of the
Paediatric Diseases Working Party of the European Group for
Blood and Marrow Transplantation on outcome after HSCT in
pediatric patients over the last 3 decades showed that age more than
14 years significantly correlated with higher TRM, both in univari-
ate and multivariate analysis.30
In contrast with all these data, our study provides evidence that
the outcome after HSCT for ALL in CR2 is similar in children and
adolescents when both are treated in the same pediatric institutions,
in the same period.
The strength of our analysis lies in the even distribution of initial
clinical and hematologic features between children and adolescents and
in the uniformity of the anti-leukemia frontline therapy administered
according to the current AIEOP-BFM protocols.2,28,29 A homogeneous
approach in both children and adolescents also was used in the treatment
of relapse. Also the conditioning regimens used by the 11 centers
participating in the study were substantially homogeneous, without
significant differences among them.
GVHD is known to be an important factor influencing TRM and
EFS. It has been reported that among patients transplanted from an
HLA-identical sibling and given GVHD prophylaxis consisting of
a combination of methotrexate and CsA, older recipient age
(P  .0001) was the single most important risk factor for cGvHD.31
More recently, a paper published by the AIEOP-HSCT group
showed that recipient age more than 15 years significantly corre-
lated with a higher risk of cGvHD, but ultimately, however, did not
influence the probability of EFS.32 In our study, the incidence and
severity of both aGvHD and cGvHD was similar in children and
adolescents, and this observation can contribute to explain the
comparable risk of death from transplantation-related causes that
we observed in the 2 groups. Nevertheless, both aGVHD and
cGVHD were responsible for most transplantation-related deaths in
children and in adolescents, and in multivariate analysis, aGvHD
and cGvHD were risk factors with a detrimental impact on TRM.
Notably, in our cohort, the risk of disease recurrence after
HSCT also did not differ between children and adolescents.
Table 4. Multivariate analysis of variables influencing EFS, RR, and
12-month TRM overall
RR 95% CI P
EFS: risk of treatment failure
Age at transplant
Adolescents vs children 1.005 0.57-1.76 N.S.
Sex
Male vs female 0.91 0.61-1.36 N.S.
BFM class at relapse
S3  S4 vs S1  S2 2.50 1.72-3.64  .0001
HLA typing resolution
HR vs MFD 1.47 0.84-2.59 N.S.
LR vs MFD 1.24 0.78-2.00 N.S.
Conditioning regimen
TBI vs chemotherapy 2.36 0.94-5.88 .066
aGvHD
Grade I vs 0 0.31 0.17-0.56 .0001
Grade II vs 0 0.27 0.15-0.50  0.0001
Grade III vs 0 0.46 0.22-0.99 .047
Grade IV vs 0 1.24 0.64-2.41 N.S.
Year of HSCT
2000 or later vs before 2000 0.63 0.36-1.08 N.S.
Relapse
Age at transplant
Adolescents vs children 1.001 0.56-1.80 N.S.
Sex
Male vs female 1.33 0.83-2.15 N.S.
BFM class at relapse
S3  S4 vs S1  S2 2.50 1.58-3.95 .0001
Conditioning regimen
TBI vs chemotherapy 1.03 0.56-1.91 N.S.
aGvHD
Grade I vs 0 0.48 0.28-0.82 .008
Grade II vs 0 0.45 0.25-0.81 .008
Grade III vs 0 0.32 0.12-0.83 .019
Grade IV vs 0 0.06 0.01-0.47 .008
cGvHD
Limited vs absent 0.44 0.21-0.91 .026
Extensive vs absent 0.74 0.33-1.64 N.S.
Year of HSCT
2000 or later vs before 2000 0.60 0.44-1.53 N.S.
TRM
Age at transplant
Adolescents vs children 1.61 0.87-2.96 N.S.
Sex
Male vs female 1.23 0.74-2.05 N.S.
BFM class at relapse
S3  S4 vs S1 S2 1.27 0.81-1.97 N.S.
HLA typing resolution
HR vs MFD 1.55 0.87-2.76 N.S.
LR vs MFD 3.04 1.74-5.29 .0001
Conditioning regimen
TBI vs chemotherapy 0.73 0.37-1.47 N.S.
aGvHD
Grade I vs 0 0.49 0.24-0.99 .046
Grade II vs 0 0.82 0.43-1.54 N.S.
Grade III vs 0 1.50 0.63-3.55 N.S.
Grade IV vs 0 6.81 3.74-12.39  .0001
cGvHD
Limited vs absent 0.32 0.14-0.76 .0095
Extensive vs absent 0.66 0.32-1.37 N.S.
Year of HSCT
2000 or later vs before 2000 0.99 0.59-1.67 N.S.
N.S. indicates not significant.
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Concerning other variables potentially influencing leukemia re-
lapse after HSCT, we confirmed that BFM stratification in different
classes of risk is valuable in predicting disease recurrence after
transplantation, as reported in a previously published analysis by
our group.33 The role of graft-versus-leukemia (GvL) in ALL is still
debated, with some studies reporting either no effect or a limited
effect restricted to aGvHD only.34 By contrast, other analyses have
noted a correlation of GvL with acute or cGvHD.32,35 In our study,
the occurrence of both aGvHD and cGvHD decreased the risk of
leukemia relapse, and patients who did not experience aGVHD had
an increased risk of treatment failure compared with those who
developed grade I-III acute GVHD. Altogether, these data provide
support to the concept that a GVHD-related GvL effect is important
for preventing disease recurrence in childhood ALL.
The final outcome of our patients transplanted from an unre-
lated volunteer did not differ in multivariate analysis from that of
patients given HSCT from an HLA-identical sibling and the
10-year EFS of 50% observed in our cohort of unrelated HSCT
recipients compares favorably with results reported in the studies
by Bunin et al4 and Woolfrey et al.5 Indeed, we observed that for
patients transplanted after 2000 from an UD the risk of treatment-
related death was significantly lower than that of patients trans-
planted before that date, this resulting into a better probability of
EFS. We have previously provided evidence that outcome of
children with CR2 ALL given HSCT from an UD has improved
over time, and the present results confirm that currently, thanks to
the improvements HLA typing obtained through the use of
high-resolution molecular techniques and the optimization of
GVHD prevention and treatment, post-transplantation outcome is
not influenced by the type of donor used, either related or
unrelated.33 Support to this interpretation is provided by the
observation that the use of high-resolution molecular typing for
both HLA class I and II loci resulted into a significantly lower TRM
and better EFS compared with the use of low-resolution typing (see
Table 3 for details).
In conclusion, this study shows that adolescents with CR2 ALL
given HSCT from a matched sibling or an UD, performed in
pediatric centers, have an outcome that does not differ from that of
patients younger than 14 years of age. Thus, in view of these data,
patient age has not to be considered any longer a risk factor when
considering or discussing the risks and benefits of the transplant
option for pediatric patients with CR2 ALL. Information about
prognostic factors provided by the current study also can be used to
direct future strategies to further improve outcome for children
with CR2 ALL who undergo allogeneic HSCT.
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